XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease

Since we are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have multiple myeloma, not everyone who participates in this research study will receive the same dose of study drug. The dose you get will depend on the number of participants who have been enrolled in the study before you and how well they have tolerated their doses.

The study drug, cabozantinib, comes in the form of tablets which you will take by mouth. You will take your dose of cabozantinib once a day during each 28 day cycle.

Detailed instructions on how to take the study drug and which foods and drinks you will be prohibited from taking during the research study can be found in your study drug diary.

During Cycle 1, you will come into the clinic weekly (Day 1, 8, 15 and 22). For all other cycles, you will come into the clinic on Day 1 and 15.

A visit will be scheduled 30 days after you have finished or stopped taking the study drug so your doctor will be able to check your well being.

Inclusion criteria

• Relapsed/Refractory Multiple Myeloma
• Skeletal lesions suggestive of bone involvement
• Must have received at least 2 lines of prior systemic therapy for the treatment of multiple myeloma
• Must have received prior treatment with a proteasome inhibitor
• Agree to use medically accepted barrier method of contraception
• Not a candidate for ASCT, has declined the option or has relapsed after prior ASCT

Exclusion criteria

• Pregnant or breastfeeding
• Has received radiotherapy to thoracic cavity or GI tract (within 3 months of first dose of study drug), bone or brain metastasis (within 14 days of first dose) or any other site (within 28 days)
• Has received any other investigational agent within 28 days
• Primary brain tumor
• Uncontrolled, significant intercurrent or recent illness
• Cardiovascular disorder(s)
• Gastrointestinal disorder(s)